How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian designKALIL, Andre C; JUNFENG SUN.Intensive care medicine (Print). 2008, Vol 34, Num 10, pp 1804-1811, issn 0342-4642, 8 p.Article

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregressionKALIL, Andre C; LAROSA, Steven P.Lancet. Infectious diseases (print). 2012, Vol 12, Num 9, pp 678-686, issn 1473-3099, 9 p.Article

Adjunctive therapies for severe sepsisWITTEBOLE, X; COLLIENNE, C; CASTANARES-ZAPATERO, D et al.International journal of antimicrobial agents (Print). 2008, Vol 32, issn 0924-8579, S34-S38, SUP1Conference Paper

Activated protein C for the treatment of severe sepsisHOUSTON, G; CUTHBERTSON, B. H.Clinical microbiology and infection. 2009, Vol 15, Num 4, pp 319-324, issn 1198-743X, 6 p.Article

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shockDHAINAUT, Jean-Francois; ANTONELLI, Massimo; MIGNINI, Mariano A et al.Intensive care medicine (Print). 2009, Vol 35, Num 7, pp 1187-1195, issn 0342-4642, 9 p.Article

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis : Comparison with a controlled clinical trialWHEELER, Arthur; STEINGRUB, Jay; SCHMIDT, Gregory A et al.Critical care medicine. 2008, Vol 36, Num 1, pp 14-23, issn 0090-3493, 10 p.Article

Drotrecogin Alfa (Activated) in Adults with Septic ShockMARCO RANIERI, V; TAYLOR THOMPSON, B; PAYEN, Didier et al.The New England journal of medicine. 2012, Vol 366, Num 22, pp 2055-2064, issn 0028-4793, 10 p.Article

The use of drotrecogin alfa in severe falciparum malariaROBAK, O; BOJIC, A; LOCKER, G. J et al.Anaesthesia and intensive care. 2010, Vol 38, Num 4, pp 751-754, issn 0310-057X, 4 p.Article

Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsisPOOLE, Daniele; BERTOLINI, Guido; GARATTINI, Silvia et al.Lancet. Infectious diseases (print). 2009, Vol 9, Num 1, pp 67-72, issn 1473-3099, 6 p.Article

Drotrecogin Alfa in Patients With Burns and Soft Tissue InjuryBRUNSVOLD, Melissa E; ARBABI, Saman; DIMO, Mary et al.Journal of burn care & research. 2008, Vol 29, Num 4, pp 676-678, issn 1559-047X, 3 p.Article

Disseminating clinical trial results in critical careKAHN, Jeremy M.Critical care medicine. 2009, Vol 37, Num 1, issn 0090-3493, S147-S153, SUPConference Paper

Activated protein C improves survival in severe sepsis patients with elevated troponinJOHN, Jijo; AWAB, Ahmed; NORMAN, Derek et al.Intensive care medicine (Print). 2007, Vol 33, Num 12, pp 2122-2128, issn 0342-4642, 7 p.Article

Error rates among clinical pharmacists in calculating the APACHE II scoreGREENWOOD, Bonnie; SZUMITA, Paul M; LEVY, Howard et al.Pharmacotherapy. 2007, Vol 27, Num 2, pp 285-289, issn 0277-0008, 5 p.Article

Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsisLEVY, Mitchell; LEVI, Marcel; WILLIAMS, Mark D et al.Intensive care medicine (Print). 2009, Vol 35, Num 7, pp 1196-1203, issn 0342-4642, 8 p.Article

Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. CommentaryFINFER, Simon; MARCO RANIERI, V; ANTONELLI, Massimo et al.Intensive care medicine (Print). 2008, Vol 34, Num 11, issn 0342-4642, 1935-1249 [12 p.]Article

Stopping Trials Early for Benefit—Not So Fast!FAUST, Andrew C; CHUNG, Tammy; FELDMAN, Mark et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1564-1567, issn 1060-0280, 4 p.Article

Sepsis-related acute kidney injury : a protective effect of drotrecogin alfa (activated) treatment?VAN DOORN, K. J; SPAPEN, H; GEERS, C et al.Acta anaesthesiologica scandinavica. 2008, Vol 52, Num 9, pp 1259-1264, issn 0001-5172, 6 p.Article

Benefit-risk assessment of drotrecogin alfa (Activated) in the treatment of sepsisDE BACKER, Daniel.Drug safety. 2007, Vol 30, Num 11, pp 995-1010, issn 0114-5916, 16 p.Article

Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautionsGENTRY, Chris A; BUSSE GROSS, Kristin; SUD, Bhanu et al.Critical care medicine. 2009, Vol 37, Num 1, pp 19-25, issn 0090-3493, 7 p.Article

Pharmacologic Modification to Resuscitation Fluid After Thermal Injury—Is Drotrecogin Alfa the Answer to Arrest Burn Depth Progression?MEYERHOLZ, David K; PIESTER, Travis L; MCNAMARA, Andrew R et al.The Journal of trauma, injury, infection, and critical care. 2009, Vol 67, Num 5, pp 996-1003, issn 1079-6061, 8 p.Article

Using Transcutaneous Oxygen Pressure Measurements as Selection Criteria for Activated Protein C UseCHAPITAL, Alyssa D; YU, Mihae; HAO CHIH HO et al.The Journal of trauma, injury, infection, and critical care. 2008, Vol 65, Num 1, pp 30-33, issn 1079-6061, 4 p.Article

Bleeding Complications with Drotrecogin Alfa Activated (Xigris®) : A Retrospective Review of 31 Operative and 68 Non-Operative Patients with Severe SepsisTAYLOR, Benedict J. W; LEE, Sarah J; WAXMAN, Kenneth et al.The American surgeon. 2008, Vol 74, Num 10, pp 898-901, issn 0003-1348, 4 p.Conference Paper

Drotrecogin alfa (activated) in children with severe sepsis : A multicentre phase III randomised controlled trial. CommentaryOPAL, Steven M; NADEL, Simon; DAZHE WANG et al.Lancet (British edition). 2007, Vol 369, Num 9564, issn 0140-6736, 803-804,836-843 [10 p.]Article

90-DAY FOLLOW-UP OF PATIENTS TREATED WITH DROTRECOGIN ALFA (ACTIVATED) FOR SEVERE SEPSIS : A BELGIAN OPEN LABEL STUDYDECRUYENAERE, J; DE BACKER, D; SPAPEN, H et al.Acta clinica belgica (Ed. multilingue). 2009, Vol 64, Num 1, pp 16-22, issn 0001-5512, 7 p.Article

Safety and Dose-Finding Study of Activated Protein C (Drotrecogin Alfa Activated) as an Anticoagulant in End-Stage Renal Disease Patients Treated with HemodialysisBRASHA-MITCHELL, Ermira; COLLINS, Ashte; SHEHU, Lindita et al.Blood purification. 2014, Vol 37, Num 3, pp 243-248, issn 0253-5068, 6 p.Article